Cannabis vs Marijuana: What the US Reclassification Means for us

On April 23, 2026, the US Department of Justice issued a landmark order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act. After more than 50 years as a Schedule I drug grouped alongside heroin, cannabis finally received federal recognition of its medical value in the world's most scrutinised drug regulatory system. For Indian consumers, this raises an important question: what does it mean here?

Cannabis vs Marijuana: Why the Words Matter

The terms cannabis and marijuana are often used interchangeably, but the distinction carries real legal weight. Cannabis is the botanical name for the plant species Cannabis sativa L. It encompasses all varieties, from industrial hemp to the high-THC plants cultivated for recreational or medicinal purposes.

Marijuana is a colloquial term that typically refers to cannabis varieties with high levels of THC (tetrahydrocannabinol), the compound responsible for psychoactive effects. The word itself carries historical and political baggage, having been used in early 20th century US legislation to stigmatise the plant and those who used it. In scientific and medical contexts globally, including in India's regulatory framework, the preferred term is cannabis.

The distinction that matters most, legally and biologically, is not the name but the compound profile. Two numbers define the difference between a legal wellness product and a prohibited narcotic in most countries: THC content and CBD content.

What Exactly Changed in the US

The reclassification did not legalise recreational marijuana. Cannabis remains a controlled substance. What changed is its classification tier. Under the US Controlled Substances Act, Schedule I substances are defined as having no accepted medical use and a high potential for abuse. Schedule III substances have an accepted medical use with moderate to low dependence potential. Heroin and LSD remain in Schedule I. Anabolic steroids and ketamine are in Schedule III.

The shift began with a 2023 recommendation from the US Department of Health and Human Services (HHS) and the FDA, which concluded that cannabis has a currently accepted medical use for treating pain, nausea, and anorexia. President Trump's December 2025 Executive Order accelerated the process, and the DOJ's April 2026 order immediately placed FDA-approved and state-licensed medical marijuana products into Schedule III, with a broader DEA administrative hearing scheduled for June 2026 to finalise full reclassification.

The practical effects include: expanded federal research access, removal of heavy tax burdens on licensed cannabis businesses, a clearer regulatory pathway for CBD products, and, critically, a formal global signal that the plant has legitimate medical standing. As noted in coverage by Pharmacy Times, this reclassification acknowledges accepted medical use and is expected to accelerate clinical trials evaluating cannabinoid safety and efficacy internationally.

India's Legal Framework: The NDPS Act 1985 and the Ayush Ministry

India's relationship with cannabis is ancient. Bhang has been consumed during religious festivals for centuries. Ayurveda references Vijaya (Cannabis sativa) as a medicinal herb with documented therapeutic applications. But modern India governs cannabis through the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, a strict piece of legislation introduced to align with international drug control treaties.

The NDPS Act 1985 makes a critical botanical distinction. It prohibits charas (resin) and ganja (flowering tops) as narcotics carrying severe penalties. However, it explicitly excludes the leaves and seeds of the cannabis plant from this prohibition. This legal carve-out is the foundation of India's entire CBD industry.

In 2018, the Ministry of Ayush formally permitted the use of cannabis in Ayurvedic, Siddha, and Unani formulations, classifying it as Vijaya under traditional medicine. This created a regulatory pathway for licensed manufacturers to produce CBD-containing products, provided they are manufactured under an Ayush licence, comply with the Drugs and Cosmetics Act 1940, contain THC levels below 0.3%, and are sold as Ayurvedic proprietary medicines, often requiring a prescription from a registered medical practitioner for full-spectrum formulations.

Is Weed Legal in India? A Clear Answer

No, weed is not fully legal in India.
Ganja (flowers) and charas (resin) are illegal under law.
Bhang (made from leaves) is legal in many states under regulation.
CBD oil may be legal if it follows government guidelines and is used appropriately.
Under the NDPS Act 1985, cannabis is regulated based on the part of the plant and THC content. The law specifically bans the flowering tops and resin, which are the psychoactive parts of the plant. However, leaves and seeds are treated differently, which is why bhang is legally sold in licensed shops in several states.

CBD products fall into a more regulated category. Those derived from hemp with low THC levels may be permitted if they comply with AYUSH guidelines, while certain formulations may require a prescription from a registered medical practitioner.
In short, cannabis is not entirely illegal in India, but its legality depends on what form you are using and how it is regulated.

What Does the US Reclassification Mean for India?

The US decision does not change Indian law directly. The NDPS Act 1985 is domestic legislation and any reform requires action by India's Parliament or state governments. However, the global signal carries weight. India is a signatory to the 1961 UN Single Convention on Narcotic Drugs, which previously constrained domestic cannabis policy. As major Western nations move formally to acknowledge cannabis's medical legitimacy, India's regulatory bodies face increasing evidence-based pressure to refine their own framework.

For Indian CBD consumers specifically, the US reclassification means accelerated clinical research that will inform the global evidence base for cannabinoid medicine. The Trump Executive Order explicitly directed resources toward expanding medical marijuana and CBD research. More clinical trial data, more FDA submissions, and a broader international acknowledgment of CBD's therapeutic role all strengthen the scientific foundation that India's Ayush Ministry and CDSCO use when evaluating future regulation.

In practical terms, nothing has changed on the ground in India today. CBD oil legal in India remains governed by the same Ayush licensing framework. Ganja and charas remain illegal. What has changed is the direction of global policy and the quality of research that will follow.

About Qurist

Qurist operates fully within India's existing legal framework. All Qurist products are manufactured under an Ayush Ministry licence, derived from hemp leaves with THC content below 0.3%, and formulated as Ayurvedic proprietary medicines in compliance with the NDPS Act 1985 and the Drugs and Cosmetics Act 1940. Qurist's CBD oils are not recreational products. They are designed to support wellness as part of a medically supervised routine.

Qurist does not claim that its products treat, cure, or prevent any medical condition. All products are intended to complement, not replace, medical care. Anyone considering CBD should consult a registered medical practitioner, particularly for full-spectrum formulations or if they are on existing medication.

Conclusion

The cannabis vs marijuana debate is, at its core, a conversation about language, compounds, and context. The US reclassification of April 2026 is the most significant shift in global cannabis policy in over 50 years. It does not make weed legal in India, and it does not change the NDPS Act 1985. What it does is place the world's most visible drug regulator firmly on record: cannabis has medical value, and its most therapeutically relevant compound, CBD, deserves a clear, accessible regulatory home.

India already has the scaffolding for that home. The Ayush Ministry's licensing framework, the NDPS Act's leaf-seed carve-out, and the growing domestic hemp industry all point toward a country in the early stages of a considered, culturally grounded approach to cannabis wellness. As global evidence grows, India's framework is likely to evolve with it.

People Also Asked

1. Does US cannabis reclassification make weed legal in India?
No. The US decision does not change Indian law. Cannabis legality in India is still governed by the NDPS Act 1985, where ganja and charas remain illegal.

2. Is CBD oil affected by US cannabis laws?
Not directly. However, US reclassification may accelerate global research, which could influence future regulatory decisions in India over time.

3. Why is cannabis treated differently across countries?
Cannabis laws depend on local policies, historical use, and international treaties. While some countries are moving toward medical acceptance, others maintain stricter control.

4. Can CBD become more accessible in India in the future?
Possibly. As more clinical evidence emerges globally and regulatory clarity improves, India may refine its framework, especially under AYUSH-guided medical use.

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice. Please consult a qualified healthcare provider for diagnosis and treatment planning.